RxDoctor Payments Data

Tova Caram

Psychiatric/Mental Health · Poughkeepsie, NYNPI 1912658428

Payments from drug & device makers

$3,772in general payments, 2019–2025

Across 186 payments — averaging $20.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$519
  • Vanda Pharmaceuticals Inc.$344
  • Teva Pharmaceuticals USA, Inc.$302
  • Neurocrine Biosciences, Inc.$258
  • Indivior Inc.$211
  • plus $676 from 8 others

What the payments were for

  • Food & beverage$3,772100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,772 in reported general payments places this provider in the 85th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$42,704
Medicare patients
51
Services billed
374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl130$189,225
RexultiBrexpiprazole47$73,794
Abilify MaintenaAripiprazole24$65,322
PerserisRisperidone12$38,502
TrintellixVortioxetine Hydrobromide24$11,564
Lurasidone Hcl103$8,104
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine118$4,183
Quetiapine Fumarate199$3,092
Trazodone Hcl272$2,560
Sertraline Hcl148$2,362
Ramelteon25$2,347
Bupropion XlBupropion Hcl171$2,345
Aripiprazole66$2,279
Buspirone Hcl104$1,968
Venlafaxine Hcl ErVenlafaxine Hcl174$1,930

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,463$189,225130 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$78$139,11671 claims
Indivior Inc.Perseris$211$38,50212 claims
Teva Pharmaceuticals USA, Inc.Loxapine$302$1,11034 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Poughkeepsie

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →